Disclosed positions
| KINIKSA PHARMACEUTICALS INTL | KNSA | ORD SHS CL A | $58,710,577 | 918,070 | SH | None |
| RELAY THERAPEUTICS INC | RLAY | COM | $55,832,979 | 2,984,125 | SH | None |
| LB PHARMACEUTICALS INC | LBRX | COM SHS | $44,663,240 | 1,376,159 | SH | None |
| RELMADA THERAPEUTICS INC | RLMD | COM | $44,227,990 | 6,391,328 | SH | None |
| ALTO NEUROSCIENCE INC | ANRO | COM SHS | $35,706,910 | 1,353,047 | SH | None |
| DIANTHUS THERAPEUTICS INC | DNTH | COM | $34,587,464 | 354,816 | SH | None |
| ALKERMES PLC | ALKS | SHS | $28,496,383 | 543,876 | SH | None |
| SAVARA INC | SVRA | COM | $21,267,868 | 3,452,576 | SH | None |
| VAXCYTE INC | PCVX | COM | $17,790,512 | 306,047 | SH | None |
| ENLIVEN THERAPEUTICS INC | ELVN | COM | $16,697,055 | 329,006 | SH | None |
| ENANTA PHARMACEUTICALS INC | ENTA | COM | $15,873,698 | 1,088,731 | SH | None |
| PERSPECTIVE THERAPEUTICS INC | CATX | COM NEW | $12,596,305 | 3,693,931 | SH | None |
| INFLARX NV | Unresolved | COM | $11,988,924 | 5,352,198 | SH | None |
| SURROZEN INC | SRZN | COM NEW | $11,211,438 | 432,040 | SH | None |
| ALUMIS INC | ALMS | COM | $11,047,032 | 392,574 | SH | None |
| CENTURY THERAPEUTICS INC | IPSC | COM | $9,944,682 | 4,059,054 | SH | None |
| MINERVA NEUROSCIENCES INC | NERV | COM NEW | $9,188,025 | 1,655,500 | SH | None |
| SAB BIOTHERAPEUTICS INC | SABS | COM NEW | $8,574,158 | 2,198,502 | SH | None |
| AN2 THERAPEUTICS INC | ANTX | COM | $8,039,593 | 1,661,073 | SH | None |
| ERASCA INC | ERAS | COM | $7,740,988 | 422,543 | SH | None |
| INHIBIKASE THERAPEUTICS INC | IKT | COM NEW | $7,270,654 | 3,581,603 | SH | None |
| RESEARCH ALLIANCE CORP III | Unresolved | ORD SHS CL A | $5,350,000 | 500,000 | SH | None |
| HELIX ACQUISITION CORP III | HLXC | USD CL A ORD SHS | $5,320,000 | 500,000 | SH | None |
| ZAI LAB LTD | ZLAB | ADR | $5,303,090 | 279,110 | SH | None |
| ACHIEVE LIFE SCIENCE INC | ACHV | COM | $4,810,240 | 736,637 | SH | None |
| LEXEO THERAPEUTICS INC | LXEO | COM | $4,322,600 | 928,593 | SH | None |
| ALECTOR INC | ALEC | COM | $4,223,147 | 2,101,068 | SH | None |
| LEONABIO INC | LONA | COM | $3,618,112 | 393,701 | SH | None |
| CORVUS PHARMACEUTICALS INC | CRVS | COM | $3,459,880 | 231,585 | SH | None |
| JATT II ACQUISITION CORP | Unresolved | ORD SHS | $1,817,600 | 160,000 | SH | None |
No matching rows. Clear the filter to see all records.
Largest 50 positions by reported value; the filing may contain more positions.
How amendments affect these holdings
This view uses 1 effective filing version(s). A restatement replaces the previous book; a new-holdings amendment adds positions. 3 positions lack a resolved ticker and 0 positions are put or call entries.
A 13F is a delayed quarterly snapshot of disclosed holdings. It is not a complete trade ledger and does not reveal every position in a manager's portfolio. Option values refer to the reported underlying position rather than a traded option premium.
Quarter end and public filing date
Use the filing's public availability date when constructing a historical observation. The quarter-end report period is earlier and cannot be substituted for when the public learned the holdings.